Neuroimaging Core

核心F：NIC摘要/摘要 PITT-ADRC的总体目标是执行和促进研究，以增加我们的 了解：1）阿尔茨海默病（AD）的病因和发病机制，2）潜在的机制 AD的认知和行为症状，以及3）制定策略，将导致有效的早期 AD和相关痴呆症的诊断和治疗。神经影像学核心（NIC）将支持这些 通过开发和应用尖端的神经影像学技术， 专注于AD谱的早期和症状前阶段。 随着对临床前生物标志物的研究的继续，越来越清楚的是， 脑结构成像数据可能是识别AD早期病理表现的关键， 任何有意义的临床变化。NIC将继续开发和分发用于获取和 解释脑功能和结构成像数据，以支持AD研究。NIC将推进 该中心的目标是通过支持和促进研究，增加我们对病因学的理解， 本发明的目的是提供一种有效的治疗AD的方法，其有助于开发用于监测治疗性AD的新疗法和方法。 功效NIC维护通过临床核心登记的个人的结构成像数据集， 我们将继续致力于前沿分析技术和新型放射性示踪剂配体的发展 用正电子发射断层扫描（PET）测量（即，PiB，AV-1451和GTP-1）。 国家信息中心的工作将通过识别 成像生物标志物以监测疾病的自然史和治疗史。精心策划的，“试验准备” 参与者数据库将允许PITT-ADRC研究人员跟踪基于生物标志物的临床进展， 确定风险和保护因素。该数据库还将独特地定位PITT-ADRC，以识别潜在的 参与者基于特定的生物标志物特征。最后，NIC对质量保证的关注将 确保神经影像学方法产生的数据测量他们声称要测量的东西， 分析流保持这些数据的完整性，确保统计方法生成模型 有生物学意义的东西。

Core F: NIC Summary/Abstract The overall goal of the PITT-ADRC is to perform and promote research that increases our understanding of: 1) the etiology and pathogenesis of Alzheimer's disease (AD), 2) the mechanisms underlying the cognitive and behavioral symptoms of AD, and 3) to develop strategies that will result in effective early diagnoses and treatments for AD and related dementias. The Neuroimaging Core (NIC) will support these Center-wide goals by developing and applying cutting edge neuroimaging technology to studies that are focused on early and presymptomatic stages of the AD spectrum. As the search for preclinical biomarkers continues, it is becoming increasingly clear that functional and structural brain imaging data may hold the key to identifying the earliest pathological manifestations of AD prior to any meaningful clinical change. The NIC will continue to develop and distribute technology for acquiring and interpreting brain functional and structural imaging data in the support of AD research. The NIC will advance the Center goals by supporting and promoting research that increases our understanding of the etiology and pathogenesis of AD and facilitates the development of new therapies and methods for monitoring therapeutic efficacy. The NIC maintains data sets of structural imaging on individuals enrolled through the Clinical Core, and we continue to work on the expansion of leading-edge analytic technologies, and novel radiotracer ligands measured with Positron Emission Tomography (PET) (i.e., PiB, AV-1451 and GTP-1). The work of the NIC will accelerate efforts to identify early and presymptomatic AD by identifying imaging biomarkers to monitor the natural and treated history of the disease. The curated, “trial-ready” participant database will allow PITT-ADRC researchers to track biomarker-based clinical progression and to identify risk and protective factors. This database will also uniquely position the PITT-ADRC to identify potential participants based on specific biomarker characteristics. Finally, the NIC’s focus on quality assurance will ensure that neuroimaging methods are generating data measuring what they purport to measure and that the analysis stream retains the integrity of these data, ensuring that the statistical methodologies generate model that are biologically meaningful.